SuperGen ceo joins BIO board

James Manuso joins the US-based biotechnology organisation

James Manuso, chief executive of SuperGen, a US developer of novel cancer therapies, has been elected to the board of the Biotechnology Industry Organization (BIO), based in Washington, DC.

BIO’s board includes members of the governing boards for each of the organisation’s four sections: health, emerging companies, industrial and environmental and food and agriculture. Manuso has joined BIO’s health section governing board.

In addition, Manuso will serve on the BIO board Standing Committee on International Affairs.

SuperGen has been a member of BIO since 2003.

Manuso has been SuperGen chairman, president and chief executive since January 2004. He is co-founder and immediate past president and chief executive of Galenica Pharmaceuticals.

The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, biotechnology centres and related organisations across the US and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

You may also like

Finance

SuperGen to acquire Astex Therapeutics

Creating an international developer of cancer drugs
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Pharmaceutical

White paper: Leadership as the missing control in the Pharmaceutical Quality System (PQS)

Why senior management determines the effectiveness of the pharmaceutical quality system
Regulatory

Oncopeptides to seek EMA label expansion for Pepaxti to include third-line multiple myeloma treatment

The company has said it will submit a Type II variation to the EMA to expand Pepaxti's indication to include patients with multiple myeloma who have received at least two prior lines of therapy — a move that would double the addressable patient population and treatment cycle potential in Europe
Subscribe now